About A public-private partnership that supports the discovery of new medicines through open access research. Mission and Philosophy Partners Governance Collaborators Laboratories Key Achievements Research Collaborations and Communications Why Companies Enter Open Science Partnerships with SGC SGC Open Science Policy Equity, Diversity and Inclusion FAQs Science TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM PROTEIN STRUCTURES PUBLICATIONS CHEMICAL PROBES Donated chemical probes Biological probes Human Kinase Chemical Probe Program Probes against other protein classes RECOMBINANT ANTIBODIES Structure-guided Drug Discovery Coalition (SDDC) SDDC Publications CREATE ChemNET Research Program Trainees Open Access Learning Impact Faculty & Industry Participants Structural & Chemical Biology Bootcamp Events Structural Biology Programme Structural Parasitology Rare Diseases Genome Integrity and Neurodegeneration Growth Factor Signalling Integral Membrane Proteins Metabolic Enzymes Phosphorylation-Dependent Signalling Protein Kinases Ubiquitin Biology Chemical Biology Antibodies Protein Families Methyl Lysine Readers Histone Deacetylases Histone Acetyltransferases Demethylases Bromodomains Protein Methyltransferases Probe Development Screening Platforms Epigenetic Cell Assays Fragment Based Screening Informatics Medicinal Chemistry ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees Histone Tails Epigenetics Pocketome Technological Science Biotechnology Biophysics Screening Platforms Research Informatics Protein Crystallography Medicinal Chemistry Reagents & Resources Reagents Chemical Probes Antibodies SGC Vectors SGC Plasmids SGC Constructs Resources Structure Gallery Protein Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees Histone Tails Fragment Screening Crystal Forms Fragalysis MichaelaNGLo Technologies High Throughput Protein Crystallisation Lex Bubbling System Frapid People Global SGC Director Aled Edwards Susan McCormick Max Morgan Academic Collaborators Industrial/ SME collaborators Non-Scientists SGC OCN Mat Todd SGC Neuro Edward Fon Ziv Gan-Or Thomas Durcan Roxanne Lariviere Peter McPherson Jean-François Trempe Carl Laflamme Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Peter J. Brown Jinrong Min Takis Prinos Matthieu Schapira Masoud Vedadi Levon Halabelian Biotechnology Crystallography UNC Tim Willson Alison Axtman David Drewry Karolinska Michael Sundström Susanne Gräslund Louise Berg Per-Johan Jakobsson Frankfurt Stefan Knapp Susanne Müller-Knapp Apirat Chaikuad Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec News & Outreach News & Events SGC News Symposia & Workshops Blog Press Releases Public Events Public Engagement SGC Languages General Public Open Lab Notebooks Schools Media Patient Groups Governments TOronto Ubiquitin Club And Network (TOUCAN) Careers Tweets by thesgconline
A public-private partnership that supports the discovery of new medicines through open access research.
GSK8814 A chemical probe for ATAD2 and ATAD2BThis probe and its negative control are available from Sigma. For any inquiries please contact proberequests@thesgc.org.group newOverview GSK8814 GSK8815 (negative control) ATAD2 and ATAD2B are chromatin remodelling factors and modulate the expression of multiple tumour cell growth factors. ATAD2 overexpression correlates with poor outcomes in several cancers. The bromodomain module of ATAD2 has been shown to be essential for its association with acetylated chromatin and presumable function. GSK8814 is a chemical probe for the ATAD2/2B bromodomain, with a binding constant pKd=8.1 as measured by ITC (Bamborough et al, 2016). GSK8814 displaces acetylated H4 peptide from the ATAD2 bromodomain with pIC50 =7.3 and is also active in BROMOscan with pKi=8.9. It is more than 100 fold selective over all other bromodomains in the BROMOscan. Importantly, it is more than 1000 fold selective over BRD4. GSK8814 shows cellular target engagement with an EC50 of 2 µM in a NanoBRET assay evaluating the interaction of the NanoLuc-ATAD2 bromodomain with histone H3.3-HaloTag. GSK8815 is a companion control compound with strongly reduced potency against ATAD2 (pKd=5.5). Properties GSK8814 GSK8815 (negative control) Physical and chemical properties for GSK8814 Molecular weight 527.3 Molecular formula C28H35F2N5O3 IUPAC name 10-(3-((4,4-difluoro-cyclohexyl)-methoxy)-5-methoxy-piperidin-4-ylamino)-4-methyl-7-(5-methyl-pyridin-3-yl)-2,9-diaza-bicyclo[4.4.0]deca-1(10),4,6,8-tetraen-3-one MollogP 3.212 PSA 78.42 No. of chiral centres 3 No. of rotatable bonds 7 No. of hydrogen bond acceptors 7 No. of hydrogen bond donors 3 Physical and chemical properties for GSK8815 (Negative Control) Molecular weight 527.3 Molecular formula C28H35F2N5O3 IUPAC name 10-(3-((4,4-difluoro-cyclohexyl)-methoxy)-5-methoxy-piperidin-4-ylamino)-4-methyl-7-(5-methyl-pyridin-3-yl)-2,9-diaza-bicyclo[4.4.0]deca-1(10),4,6,8-tetraen-3-one MollogP 3.212 PSA 78.42 No. of chiral centres 3 No. of rotatable bonds 7 No. of hydrogen bond acceptors 7 No. of hydrogen bond donors 3 SMILES: GSK8814: CC1=Cc2c(cnc(c2NC1=O)N[C@@H]1[C@H](CNC[C@H]1OCC1CCC(CC1)(F)F)OC)c1cc(C)cnc1 GSK8815: CC1=Cc2c(cnc(c2NC1=O)N[C@@H]1[C@H](CNC[C@H]1OC)OCC1CCC(CC1)(F)F)c1cc(C)cnc1 InChI: GSK8814: InChI=1S/C28H35F2N5O3/c1-16-8-19(11-31-10-16)21-12-33-26(24-20(21)9-17(2)27(36)35-24)34-25-22(37-3)13-32-14-23(25)38-15-18-4-6-28(29,30)7-5-18/h8-12,18,22-23,25,32H,4-7,13-15H2,1-3H3,(H,33,34)(H,35,36)/t22-,23+,25+/m0/s1 GSK8815: InChI=1S/C28H35F2N5O3/c1-16-8-19(11-31-10-16)21-12-33-26(24-20(21)9-17(2)27(36)35-24)34-25-22(37-3)13-32-14-23(25)38-15-18-4-6-28(29,30)7-5-18/h8-12,18,22-23,25,32H,4-7,13-15H2,1-3H3,(H,33,34)(H,35,36)/t22-,23+,25+/m1/s1 InChIKey: GSK8814: YDPMMWAOCCOULO-JBRSBNLGSA-N GSK8815: YDPMMWAOCCOULO-CUYJMHBOSA-N ReferencesBamborough P, Chung CW, Demont EH, Furze RC, Bannister AJ, Che KH, Diallo H, Douault C, Grandi P, Kouzarides T, Michon AM, Mitchell DJ, Prinjha RK, Rau C, Robson S, Sheppard RJ, Upton R, Watson RJ. A Chemical Probe for the ATAD2 Bromodomain. Angew Chem Int Ed Engl. 2016, 55(38):11382-6.